CN105597140A - Medical micro-porous biological hemostatic material and preparation method thereof - Google Patents

Medical micro-porous biological hemostatic material and preparation method thereof Download PDF

Info

Publication number
CN105597140A
CN105597140A CN201610042924.7A CN201610042924A CN105597140A CN 105597140 A CN105597140 A CN 105597140A CN 201610042924 A CN201610042924 A CN 201610042924A CN 105597140 A CN105597140 A CN 105597140A
Authority
CN
China
Prior art keywords
collagen
medical micro
hemostatic material
hyaluronic acid
lasiosphaera fenzlii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610042924.7A
Other languages
Chinese (zh)
Inventor
梁奕福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dongguan Da Qing Medical Devices Co Ltd
GUANGXI XINYE BIOLOGICAL TECHNOLOGY Co Ltd
Guangxi Daqing Biotechnology Co Ltd
Original Assignee
Dongguan Da Qing Medical Devices Co Ltd
GUANGXI XINYE BIOLOGICAL TECHNOLOGY Co Ltd
Guangxi Daqing Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan Da Qing Medical Devices Co Ltd, GUANGXI XINYE BIOLOGICAL TECHNOLOGY Co Ltd, Guangxi Daqing Biotechnology Co Ltd filed Critical Dongguan Da Qing Medical Devices Co Ltd
Priority to CN201610042924.7A priority Critical patent/CN105597140A/en
Publication of CN105597140A publication Critical patent/CN105597140A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/102—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The invention relates to a bio-medicine hemostatic material, in particular to a medical micro-porous biological hemostatic material and a preparation method thereof. The medical micro-porous biological hemostatic material is composed of collagen, hyaluronic acid and puffball spore powder. Collagen can be rapidly combined with hemoglobin in blood to form hemostatic clots, and in addition, after collagen and wounds are tightly combined, collagen can permeate into regenerated tissue and serve as a support for cell growth; hyaluronic acid can instantly absorb water in blood to form hydrogel, and therefore exudation is blocked; the three substances form physical barriers, isolate wounds, and achieve the effects of adhesion prevention and instant hemostasis. The medical micro-porous biological hemostatic material is used for hemostasis of exudation of various wounds and fresh tissue wound surfaces, small vessel bleeding and bleeding regions, and prevents adhesion.

Description

Biological hemostatic material of a kind of medical micro porouse and preparation method thereof
Technical field
The present invention relates to biological medicine hemostatic material technical field, be specifically related to the biological hemostatic material of a kind of medical micro porouse andIts preparation method.
Background technology
Hemostasis is an important step in the operation of each section office of hospital, plays phase for the success of operation and patient's safetyWhen large effect. Normal hemostatic mechanism mainly comprises 3 aspects: the contraction of little blood vessel, hematoblastic activation and blood coagulation systemStartup. Wherein, the contraction of little blood vessel is the reaction the earliest of stopping blooding after wound, and after vascular injury, vascular smooth muscle is anti-by aixs cylinderPenetrate vessel retraction, blood flow are slowed down, be conducive to blood clotting and hemostasis. Blood platelet has the life that adheres to wound and foreign matter surfaceReason function, significant at the hemostasis initial stage. The blood platelet adhering to is activated and may causes more platelet aggregation, andDischarge a large amount of short condensates from its inside, and then stop blooding at Local Shape thromboblast thrombus. Due to environmental factor or peopleBody oneself factor, normal haemostasis mechanism can not be saved the wounded for the injured large-area hemorrhage of human body and be about to the life disappearing. CauseThis, the research rapidly hemostatic material of hemostasis is important research topic.
Traditional hemostatic material mainly comprises first-aid dressing, tourniquet, gauze etc. These auxiliary materials only play physical protection to the surface of a woundEffect, function and effect are single, and haemostatic effect is not good enough, and is easily adhered the surface of a wound.
Along with the development of technology, there is starch hemostatic material, as the China that application number is 200810032631.6 inventsPatent Application Publication the modified starch material of a kind of biocompatible hemostatic, prevent adhesion, promoting healing, surgery sealing, this hemostasisMaterial is the mixture of esterification starch or one or more esterifications, crosslinked starch. The molecular weight of modified starch is 15,000 ~10,000,000, particle diameter is 10 ~ 1000 μ m, and water absorption rate is 1 ~ 100.
But these current technology haemostatic effects are undesirable, and anthemorrhagic speed is fast not, limit it in clinical extensively shouldWith.
Summary of the invention
The object of the invention is to for the deficiencies in the prior art, the doctor that a kind of anthemorrhagic speed is fast, haemostatic effect is good is providedWith the biological hemostatic material of micropore.
To achieve these goals, the present invention adopts following technical scheme:
The biological hemostatic material of a kind of medical micro porouse, the biological hemostatic material of described medical micro porouse is by the raw material group of following percentage by weightBecome:
Collagen 20-40%
Hyaluronic acid 20-40%
Lasiosphaera fenzlii conidia powder 20-40%.
Preferably, the biological hemostatic material of described medical micro porouse is made up of the raw material of following percentage by weight:
Collagen 30-35%
Hyaluronic acid 30-35%
Lasiosphaera fenzlii conidia powder 30-35%.
Another is preferred, and the biological hemostatic material of this medical micro porouse is made up of the raw material of following percentage by weight:
Collagen 25-30%
Hyaluronic acid 35-40%
Lasiosphaera fenzlii conidia powder 30-35%.
More preferred, the biological hemostatic material of this medical micro porouse is made up of the raw material of following percentage by weight:
Collagen 30%
Hyaluronic acid 40%
Lasiosphaera fenzlii conidia powder 30%.
Preferably, described hyaluronic acid is that mean molecule quantity is the daltonian pharmaceutical grade powder of 500-2000.
Preferably, collagen is that mean molecule quantity is the daltonian pharmaceutical grade collagen of 500-2000.
Preferably, described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, digs out content and sifts out spore, and spore is existed110-130 degree Celsius dry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Described collagen is nanoscale collagen.
A preparation method for the biological hemostatic material of medical micro porouse, mixes collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powderObtain the biological hemostatic material of a kind of medical micro porouse.
Preferably, collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder mix rear continuation ultrasonic vibration 1-5 hour,Ultrasonic vibration can make the more even of each raw material mixing, plays the effect that drug effect evenly discharges.
The collagen fast hemoglobin in blood is combined, and forms hemostasis grumeleuse, the shutoff of mechanical-physicalCapillary oozing of blood, after collagen and wound are combined closely in addition, can infiltrate in the middle of cambium, and during as Growth of CellsSupport; Preferably collagen employing mean molecule quantity is the daltonian pharmaceutical grade collagen of 500-2000; Due to collagen eggWhite rank, absorption and the haemostatic effect that molecular weight can directly affect collagen, 500-2000 dalton molecule weight rangeThe most applicable skin of collagen absorbs, and is the daltonian pharmaceutical grade collagen of 500-2000 egg so the present invention selects mean molecule quantityIn vain.
Nanoscale collagen is because its unique molecular weight and molecular structure make it have and be different from common collagenThe uniqueness of albumen. In absorption efficiency, nanometre collagen albumen can be without any physics of human body, chemical digestion effect andUtilization is directly absorbed by the body. In regeneration, nanometre collagen albumen can be more accurately, the complete required portion of arrival healthPosition, its distinctive three-D space structure collagen of synthetic macromolecule amount faster, and utilized fast by human body.
Hyaluronic acid demonstrates multiple important physiological function with its unique molecular structure and physicochemical property in body,Hyaluronic acid of the present invention has the effect such as permeability, Water-Electrolyte diffusion and running, promotion wound healing that regulates vascular wall.It is the daltonian pharmaceutical grade powder of 500-2000 that the acid of preferably clear matter adopts mean molecule quantity; Due to hyaluronic purity, pointSon amount is the hyaluronic effect of impact directly, is the daltonian pharmaceutical grade of 500-2000 so the present invention selects mean molecule quantityPowder.
Lasiosphaera fenzlii, nature and flavor are pungent, flat, nontoxic, containing Argine Monohydrochloride, the acid of cheese base, urea, ergosterol, lipoids, Lasiosphaera fenzliiElement etc., have anti-inflammatory, antibacterial, hemostasis effect. Preferably Lasiosphaera fenzlii conidia powder refers to Lasiosphaera fenzlii is peelled off to exoperidium, digs out content sieveGo out spore, spore is crossed to the Lasiosphaera fenzlii conidia powder that obtains with upper screen cloth of 100 orders at 110-130 degree Celsius after dry, pulverize. Through withThe Lasiosphaera fenzlii conidia powder of upper processing has better antibacterial, haemostatic effect. Lasiosphaera fenzlii conidia powder stores a large amount of micro-porous fibres, can be fastThe moisture of speed in absorbing blood, can mechanicalness shutoff blood vessel cut and capillary oozing of blood, and this physical barriers can be isolated wound simultaneouslyMouthful, play the effect of instant hemostasis.
The nano level collagen of the present invention and excessively 100 orders, can be mutual on particle diameter with the Lasiosphaera fenzlii conidia powder of upper screen clothCoordinate, avoided the reunion of nanometre collagen albumen, the high surface energy that has utilized again nanometre collagen albumen to have, it and wound face are tiedClose closelyr, make haemostatic effect better rapider.
Compared with prior art, beneficial effect is in the present invention:
(1) collagen of the present invention fast the hemoglobin in blood be combined, form hemostasis grumeleuse, mechanical-physicalShutoff capillary oozing of blood, after collagen and wound are combined closely in addition, can infiltrate in the middle of cambium, and as cellSupport when growth; Hyaluronic acid immediately in absorbing blood moisture form hydrogel, thereby shutoff oozing of blood; The storage of Lasiosphaera fenzlii conidia powderHave a large amount of micro-porous fibres, the moisture in absorbing blood rapidly, can mechanicalness shutoff blood vessel cut and capillary oozing of blood.Collagen, hyaluronic acid, this three of Lasiosphaera fenzlii conidia powder form physical barriers jointly, can isolate wound, play prevent adhesion and areThe effect of time hemostasis. For the hemostasis in various wounds and flesh tissue blood oozing from the wound surface, little angiorrbagia and hemorrhage district, antiseized in advanceConnect.
(2) the biological hemostatic material biocompatibility of medical micro porouse of the present invention meets GB/T16886.11-2011 requirement,The biological hemostatic material microbiological indicator of medical micro porouse meets GB15979-2002 requirement.
(3) the present invention can stop blooding rapidly, and the gel viscosity of formation is higher, can clog damaged tissues and blood vessel, and the present invention existsEasily swelling and cleaning in water, residue greatly reduces; The present invention is stable and be difficult for decomposition, and long shelf-life, has storage advantage.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further illustrated.
Embodiment 1.
The biological hemostatic material of a kind of medical micro porouse, is made up of the raw material of following percentage by weight:
Collagen 20%
Hyaluronic acid 40%
Lasiosphaera fenzlii conidia powder 40%.
Described hyaluronic acid is that mean molecule quantity is 500 daltonian pharmaceutical grade powder.
Described collagen is that mean molecule quantity is 1000 daltonian pharmaceutical grade collagens.
Described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, dig out content and sift out spore, by spore at 110 degrees CelsiusDry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Above-mentioned collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder are mixed to get to the biological hemostatic material of a kind of medical micro porouse.
Embodiment 2.
The biological hemostatic material of a kind of medical micro porouse, is made up of the raw material of following percentage by weight:
Collagen 40%
Hyaluronic acid 20%
Lasiosphaera fenzlii conidia powder 40%.
Described hyaluronic acid is that mean molecule quantity is 1000 daltonian pharmaceutical grade powder.
Described collagen is that mean molecule quantity is 500 daltonian pharmaceutical grade collagens.
Described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, dig out content and sift out spore, by spore at 120 degrees CelsiusDry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Described collagen is nanoscale collagen.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder are mixed to get to the biological hemostatic material of a kind of medical micro porouse.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder mix rear continuation ultrasonic vibration 2 hours.
Embodiment 3.
The biological hemostatic material of a kind of medical micro porouse, is made up of the raw material of following percentage by weight:
Collagen 40%
Hyaluronic acid 40%
Lasiosphaera fenzlii conidia powder 20%.
Described hyaluronic acid is that mean molecule quantity is 2000 daltonian pharmaceutical grade powder.
Described collagen is that mean molecule quantity is 900 daltonian pharmaceutical grade collagens.
Described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, dig out content and sift out spore, by spore at 130 degrees CelsiusDry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Described collagen is nanoscale collagen.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder are mixed to get to the biological hemostatic material of a kind of medical micro porouse.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder mix rear continuation ultrasonic vibration 5 hours.
Embodiment 4.
The biological hemostatic material of a kind of medical micro porouse, is made up of the raw material of following percentage by weight:
Collagen 30%
Hyaluronic acid 40%
Lasiosphaera fenzlii conidia powder 30%.
Described hyaluronic acid is that mean molecule quantity is 1000 daltonian pharmaceutical grade powder.
Described collagen is that mean molecule quantity is 1500 daltonian pharmaceutical grade collagens.
Described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, dig out content and sift out spore, by spore at 130 degrees CelsiusDry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Described collagen is nanoscale collagen.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder are mixed to get to the biological hemostatic material of a kind of medical micro porouse.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder mix rear continuation ultrasonic vibration 3 hours.
Embodiment 5.
The biological hemostatic material of a kind of medical micro porouse, is made up of the raw material of following percentage by weight:
Collagen 25%
Hyaluronic acid 35%
Lasiosphaera fenzlii conidia powder 40%.
Described hyaluronic acid is that mean molecule quantity is 1800 daltonian pharmaceutical grade powder.
Described collagen is that mean molecule quantity is 500 daltonian pharmaceutical grade collagens.
Described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, dig out content and sift out spore, by spore at 120 degrees CelsiusDry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Described collagen is nanoscale collagen.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder are mixed to get to the biological hemostatic material of a kind of medical micro porouse.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder mix rear continuation ultrasonic vibration 4 hours.
Embodiment 6.
The biological hemostatic material of a kind of medical micro porouse, is made up of the raw material of following percentage by weight:
Collagen 40%
Hyaluronic acid 35%
Lasiosphaera fenzlii conidia powder 25%.
Described hyaluronic acid is that mean molecule quantity is 1000 daltonian pharmaceutical grade powder.
Described collagen is that mean molecule quantity is 1000 daltonian pharmaceutical grade collagens.
Described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, dig out content and sift out spore, by spore at 120 degrees CelsiusDry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Described collagen is nanoscale collagen.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder are mixed to get to the biological hemostatic material of a kind of medical micro porouse.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder mix rear continuation ultrasonic vibration 5 hours.
Embodiment 7.
The biological hemostatic material of a kind of medical micro porouse, is made up of the raw material of following percentage by weight:
Collagen 35%
Hyaluronic acid 25%
Lasiosphaera fenzlii conidia powder 40%.
Described hyaluronic acid is that mean molecule quantity is 1200 daltonian pharmaceutical grade powder.
Described collagen is that mean molecule quantity is 800 daltonian pharmaceutical grade collagens.
Described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, dig out content and sift out spore, by spore at 120 degrees CelsiusDry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Described collagen is nanoscale collagen.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder are mixed to get to the biological hemostatic material of a kind of medical micro porouse.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder mix rear continuation ultrasonic vibration 3 hours.
Embodiment 8.
The biological hemostatic material of a kind of medical micro porouse, is made up of the raw material of following percentage by weight:
Collagen 35%
Hyaluronic acid 38%
Lasiosphaera fenzlii conidia powder 27%.
Described hyaluronic acid is that mean molecule quantity is 500 daltonian pharmaceutical grade powder.
Described collagen is that mean molecule quantity is 1000 daltonian pharmaceutical grade collagens.
Described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, dig out content and sift out spore, by spore at 120 degrees CelsiusDry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Described collagen is nanoscale collagen.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder are mixed to get to the biological hemostatic material of a kind of medical micro porouse.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder mix rear continuation ultrasonic vibration 5 hours.
Embodiment 9.
The biological hemostatic material of a kind of medical micro porouse, is made up of the raw material of following percentage by weight:
Collagen 30%
Hyaluronic acid 20%
Lasiosphaera fenzlii conidia powder 38%
Herba Cirsii extract 1%
Madder extract 1%
Receptaculum nelumbinis extract 1%
Flos Sophorae extract 1%
Notogineng Extract 1%
Pollen Tyjphae extract 1%
Duanxueliu extract 1%
SIJIQING extract 1%
Lignum Dalbergiae Odoriferae extract 1%
Corydalis P.E 1%
Herba Artemisiae Anomalae extract 1%
Japanses beauty-berry grass extract 1%.
Described hyaluronic acid is that mean molecule quantity is 1200 daltonian pharmaceutical grade powder.
Described collagen is that mean molecule quantity is 800 daltonian pharmaceutical grade collagens.
Described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, dig out content and sift out spore, by spore at 120 degrees CelsiusDry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Described collagen is nanoscale collagen.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder and each Chinese medical extract are mixed to get to a kind of medical micro porouse biologyHemostatic material.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder and each Chinese medical extract mix 3 of rear continuation ultrasonic vibrationsHour.
Embodiment 10.
The biological hemostatic material of a kind of medical micro porouse, is made up of the raw material of following percentage by weight:
Collagen 33%
Hyaluronic acid 36%
Lasiosphaera fenzlii conidia powder 25%.
Herba Cirsii extract 0.5%
Madder extract 0.5%
Receptaculum nelumbinis extract 0.5%
Flos Sophorae extract 0.5%
Notogineng Extract 0.5%
Pollen Tyjphae extract 0.5%
Duanxueliu extract 0.5%
SIJIQING extract 0.5%
Lignum Dalbergiae Odoriferae extract 0.5%
Corydalis P.E 0.5%
Herba Artemisiae Anomalae extract 0.5%
Japanses beauty-berry grass extract 0.5%.
Described hyaluronic acid is that mean molecule quantity is 500 daltonian pharmaceutical grade powder.
Described collagen is that mean molecule quantity is 1000 daltonian pharmaceutical grade collagens.
Described Lasiosphaera fenzlii conidia powder is that Lasiosphaera fenzlii is peelled off to exoperidium, dig out content and sift out spore, by spore at 120 degrees CelsiusDry, pulverize the Lasiosphaera fenzlii conidia powder that rear mistake 100 orders obtain with upper screen cloth.
Described collagen is nanoscale collagen.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder and each Chinese medical extract are mixed to get to a kind of medical micro porouse biologyHemostatic material.
Collagen, hyaluronic acid, Lasiosphaera fenzlii conidia powder and each Chinese medical extract mix 5 of rear continuation ultrasonic vibrationsHour.
Hemostasis potency assay and comparison:
Adult 50 of the healthy rabbits (Guangxi Medical University's zoopery center provides) of animal used as test and grouping, body weight 2.5-3kg,Male and female are not limit, experimental group and control group, every group each 25, interior each 5 of each pressing time section. Every rabbit both sides kidney is long1cm, the hemorrhage surface of a wound of dark 0.5cm size, stops blooding to the hemorrhage surface of a wound with the hemostatic material of embodiment of the present invention 1-10 at random, withArista styptic powder is contrast to the hemostasis of the opposite side surface of a wound. Experimental group is the application of embodiment of the present invention 1-10 hemostatic material,Control group is the application of Arista styptic powder.
Experimental technique and observation index
Hemorrhage Model is made: 3% pentobarbital sodium inj (30-40mg/kg) is anaesthetized along intravenous injection along family's rabbit ear, in experimentOn platform, fix rabbit, abdomen is successively opened in sterile working, expose rabbit kidney, with knife blade at random kidney diverse location do twoLongitudinally incised injury, is about 1cm, dark about 0.5cm, and cutting part blood is used 1g after blotting with the dry gauze that claimed weight at randomThe hemostatic material of embodiment of the present invention 1-10 stops blooding to the hemorrhage surface of a wound, taking 1gArista powder to the hemostasis of the opposite side surface of a wound asContrast, uses the gauze pressing surface of a wound, when oppressing respectively 10s, 20s, 30s, 40s, 50s and recording the amount of bleeding of each time group and stop bloodingBetween.
Hemorrhage index observing
The bleeding stopping period kidney hemorrhagic disease surface of a wound is observed: calculate and start to be applied to the surface of a wound to surface of a wound blood from the present invention or Arista styptic powderLiquid oozes out and stops or the red area that dyes of styptic powder particle no longer expands and is recorded as bleeding stopping period.
Dry gauze weight before assay balance accurate weighing experimental group and control group hemostasis in advance and after hemostasis for amount of bleeding, respectivelyCalculate blood volume (the front weight/blood specific gravity of weight-hemostasis after amount of bleeding=hemostasis).
Result: general proterties and ultra microstructure: hemostatic material of the present invention is white powder particle, visually observes, and particle is largeLittle homogeneous, grain structure is compared with Arista styptic powder exquisiteness, and under ESEM, starch granules diameter is about 20 μ m, and inside has multiplePore passage structure, aperture is about 1.5 μ m, and pore size is basic identical. Arista styptic powder is white powder particle, ESEMLower visible particle surface is made up of multiple cracks, and without pore passage structure, particle volume is about 1-2 of the present invention doubly.
Experimental result demonstration, in the time of compressing 10s, 20s, kidney hemorrhagic disease amount is large, and the bleeding time is long. Pressing time exceedes after 30s, goes outBlood volume and bleeding time change obvious, and both obviously shorten, and after compressing 40s, 50s, hemorrhage index amplitude of variation is furtherReduce. Experimental data shows: more than experimental group and control group all need to oppress 30s, haemostatic effect could embody. Table 1 is different pressureIn the time of compeling, the comparison of the hemostatic material of embodiment of the present invention 1-10 and Arista styptic powder amount of bleeding and bleeding stopping period.
Table 1
。
Can find out that by table 1 haemostatic effect of the present invention is obviously better than Arista styptic powder.
Haemostatic effect gross examination of skeletal muscle
Expose after kidney, perform an operation after otch on normal kidney surface, blood is gushed out rapidly, blot after blood with dry gauze,Spill fast 1g styptic powder of the present invention, hemorrhage district starch is reddened immediately by white, and dry gauze continues compressing. 20s compressing group,Remove gauze, the hemorrhage surface of a wound has a small amount of blood to ooze out, and the red area that dyes of styptic powder of the present invention slowly expands; 30s compressing group, kidneyOtch is hemorrhage to be stopped substantially, without obvious oozing phenomenon; 40s and 50s compressing group, remove after gauze, visible styptic powder of the present inventionAttach in the pasty state cut surface, stopped bleeding.
Finally it should be noted that above embodiment is only in order to technical scheme of the present invention to be described, but not the present invention is protectedProtect the restriction of scope, although the present invention has been done to explain with reference to preferred embodiment, those of ordinary skill in the art shouldWork as understanding, can modify or be equal to replacement technical scheme of the present invention, and not depart from the reality of technical solution of the present inventionMatter and scope.

Claims (10)

1. the biological hemostatic material of medical micro porouse, is characterized in that: the biological hemostatic material of this medical micro porouse is by following weight hundredThe raw material composition of proportion by subtraction:
Collagen 20-40%
Hyaluronic acid 20-40%
Lasiosphaera fenzlii conidia powder 20-40%.
2. the biological hemostatic material of a kind of medical micro porouse according to claim 1, is characterized in that: this medical micro porouse is only biologicalBlood material is made up of the raw material of following percentage by weight:
Collagen 30-35%
Hyaluronic acid 30-35%
Lasiosphaera fenzlii conidia powder 30-35%.
3. the biological hemostatic material of a kind of medical micro porouse according to claim 1, is characterized in that: this medical micro porouse is only biologicalBlood material is made up of the raw material of following percentage by weight:
Collagen 25-30%
Hyaluronic acid 35-40%
Lasiosphaera fenzlii conidia powder 30-35%.
4. the biological hemostatic material of a kind of medical micro porouse according to claim 1, is characterized in that: this medical micro porouse is only biologicalBlood material is made up of the raw material of following percentage by weight:
Collagen 30%
Hyaluronic acid 40%
Lasiosphaera fenzlii conidia powder 30%.
5. the biological hemostatic material of a kind of medical micro porouse according to claim 1, is characterized in that: described hyaluronic acid is for flatAverage molecular weight is the daltonian pharmaceutical grade powder of 500-2000.
6. the biological hemostatic material of a kind of medical micro porouse according to claim 1, is characterized in that: described collagen is for flatAverage molecular weight is the daltonian pharmaceutical grade collagen of 500-2000.
7. the biological hemostatic material of a kind of medical micro porouse according to claim 1, is characterized in that: described Lasiosphaera fenzlii conidia powder isLasiosphaera fenzlii is peelled off to exoperidium, digs out content and sift out spore, by spore 110-130 degree Celsius dry, pulverize after cross 100 orders withThe Lasiosphaera fenzlii conidia powder that upper screen cloth obtains.
8. the biological hemostatic material of a kind of medical micro porouse according to claim 1, is characterized in that: described collagen is for receivingMeter level collagen.
9. the preparation method of the biological hemostatic material of a kind of medical micro porouse claimed in claim 1, is characterized in that: by collagen eggIn vain, hyaluronic acid, Lasiosphaera fenzlii conidia powder are mixed to get the biological hemostatic material of a kind of medical micro porouse.
10. the preparation method of the biological hemostatic material of a kind of medical micro porouse according to claim 9, is characterized in that: collagenAlbumen, hyaluronic acid, Lasiosphaera fenzlii conidia powder mix rear continuation ultrasonic vibration 1-5 hour.
CN201610042924.7A 2016-01-22 2016-01-22 Medical micro-porous biological hemostatic material and preparation method thereof Pending CN105597140A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610042924.7A CN105597140A (en) 2016-01-22 2016-01-22 Medical micro-porous biological hemostatic material and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610042924.7A CN105597140A (en) 2016-01-22 2016-01-22 Medical micro-porous biological hemostatic material and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105597140A true CN105597140A (en) 2016-05-25

Family

ID=55977842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610042924.7A Pending CN105597140A (en) 2016-01-22 2016-01-22 Medical micro-porous biological hemostatic material and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105597140A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108619000A (en) * 2018-05-13 2018-10-09 广州圣幽兰生物科技有限公司 The hyaluronic acid oligosaccharide and collagen oligopeptide stoste of nano-spray moisturizing instrument

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001649A (en) * 2004-07-09 2007-07-18 弗罗桑公司 Haemostatic composition comprising hyaluronic acid
CN101002957A (en) * 2007-01-11 2007-07-25 西安三森生物技术有限公司 Biodegradable quick hemostyptic dressing, and its preparing method
CN101648014A (en) * 2008-08-13 2010-02-17 北京和润创新医药科技发展有限公司 Medicinal composition for treating skin injury and ulcer and application thereof
CN103349791A (en) * 2013-07-29 2013-10-16 广西信业生物技术有限公司 Novel microporous medical hemostatic material and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001649A (en) * 2004-07-09 2007-07-18 弗罗桑公司 Haemostatic composition comprising hyaluronic acid
CN101002957A (en) * 2007-01-11 2007-07-25 西安三森生物技术有限公司 Biodegradable quick hemostyptic dressing, and its preparing method
CN101648014A (en) * 2008-08-13 2010-02-17 北京和润创新医药科技发展有限公司 Medicinal composition for treating skin injury and ulcer and application thereof
CN103349791A (en) * 2013-07-29 2013-10-16 广西信业生物技术有限公司 Novel microporous medical hemostatic material and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108619000A (en) * 2018-05-13 2018-10-09 广州圣幽兰生物科技有限公司 The hyaluronic acid oligosaccharide and collagen oligopeptide stoste of nano-spray moisturizing instrument

Similar Documents

Publication Publication Date Title
CN101485897B (en) Biocompatible hemostatic, antiblocking, healing-promoting and surgical wound-closing modified starch material
US10076590B2 (en) Modified starch material of biocompatible hemostasis
CN101361986B (en) Modified starch absorbable or biocompatible hemostasia material and preparation method thereof
JP4480270B2 (en) Hemostatic sandwich bandage
CN103349791B (en) Novel microporous medical hemostatic material and preparation method thereof
WO2016133483A1 (en) Hemostatic composition and hemostatic device (variants)
JP2002513645A (en) Composition comprising a hemostatic compound and a bioabsorbable polymer
CN101455857A (en) Biocompatibility modified starch sponges
CN101497670A (en) Biocompatibility pre-gelatinized modified starch and preparation thereof
BRPI1005362B1 (en) method for preparing a wound dressing, and bank of biological wound dressings
ES2957842T3 (en) Method of making hemostatic compositions
CN105617450A (en) Biomedical porous fiber hemostatic material and preparation method thereof
CN105327383A (en) Collagen/calcium alginate/chitosan composite hemostatic sponge and making method
CN105688267A (en) Medical micro-hole composite hemostatic material and preparing method thereof
CN106975098A (en) A kind of complex polysaccharide hemostatic composition and preparation method and application
ES2741015T3 (en) Dry pad comprising thrombin and pectin
CN102791299A (en) Method for improved fibrin sealing
CN111729126B (en) Hemostatic material based on combination of chitosan and tissue factor and preparation method thereof
CN105597140A (en) Medical micro-porous biological hemostatic material and preparation method thereof
CN105561383A (en) Composite medical bio-fiber hemostasis modified material and preparation method thereof
CN105688266A (en) Composite medical biofiber bleeding-arresting powder material and preparation method thereof
CN105477676A (en) Medical bio-fiber hemostatic modified material and preparation method thereof
CN110121350A (en) Hemostatic composition comprising anionite and calcium salt
WO2014106136A1 (en) Lyophilized fibrin sealant for high volume hemorrhage
CN105597142A (en) Medical bio-fiber styptic powder material and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160525

RJ01 Rejection of invention patent application after publication